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Abstract
In this study, we characterized the metabolome of the human ovary and identified metabolic alternations that coincide with
primary epithelial ovarian cancer (EOC) and metastatic tumors resulting from primary ovarian cancer (MOC) using three
analytical platforms: gas chromatography mass spectrometry (GC/MS) and liquid chromatography tandem mass
spectrometry (LC/MS/MS) using buffer systems and instrument settings to catalog positive or negative ions. The human
ovarian metabolome was found to contain 364 biochemicals and upon transformation of the ovary caused changes in
energy utilization, altering metabolites associated with glycolysis and b-oxidation of fatty acids—such as carnitine (1.79 fold
in EOC, p,0.001; 1.88 fold in MOC, p,0.001), acetylcarnitine (1.75 fold in EOC, p,0.001; 2.39 fold in MOC, p,0.001), and
butyrylcarnitine (3.62 fold, p,0.0094 in EOC; 7.88 fold, p,0.001 in MOC). There were also significant changes in
phenylalanine catabolism marked by increases in phenylpyruvate (4.21 fold; p=0.0098) and phenyllactate (195.45 fold;
p,0.0023) in EOC. Ovarian cancer also displayed an enhanced oxidative stress response as indicated by increases in 2-
aminobutyrate in EOC (1.46 fold, p=0.0316) and in MOC (2.25 fold, p,0.001) and several isoforms of tocopherols. We have
also identified novel metabolites in the ovary, specifically N-acetylasparate and N-acetyl-aspartyl-glutamate, whose role in
ovarian physiology has yet to be determined. These data enhance our understanding of the diverse biochemistry of the
human ovary and demonstrate metabolic alterations upon transformation. Furthermore, metabolites with significant
changes between groups provide insight into biochemical consequences of transformation and are candidate biomarkers of
ovarian oncogenesis. Validation studies are warranted to determine whether these compounds have clinical utility in the
diagnosis or clinical management of ovarian cancer patients.
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Introduction
Ovarian cancer is the most lethal malignancy of the female
reproductive system and the 5
th cause of cancer death in women.
It is estimated that 21,880 women will be diagnosed and 13,850
will die from this disease this year. The five-year survival rate at
Stage I is 93.5% but drops to 27.6% at Stage IV, where a majority
of cases are diagnosed due to a lack of symptoms at the earlier
stages [1]. Current detection strategies include transvaginal
ultrasound and blood CA-125 levels. However, both detection
methods have shortcomings. With ultrasound, cancer could be
mistaken for functional cysts in pre-menopausal women due to the
dynamic nature of the ovarian surface [2]. CA-125 has a high false
positive rate [2] that can arise from a variety of conditions
including endometriosis, fibroids, hemorrhagic ovarian cysts, acute
pelvic inflammatory disease, menstruation, first trimester preg-
nancy, and several other cancer types [3]. In addition, CA-125 is
often not detectable in early stage ovarian cancer [4]. Alternative
methods are being developed for patients who have normal CA-
125 levels but are suspected to having recurrent disease based on
clinical symptoms [5]. These methods include other potential
biomarkers, the most promising being human epydidimus protein
4 (HE4), [6,7,8,9,10] despite detection rates of 50–60% in early
stage ovarian cancer. A comprehensive study comparing the
sensitivity of ovarian cancer biomarkers to discriminate between
benign and malignant masses has been described [11] as well as
the role of molecular markers in prognosis and therapy reviewed
in [12]. It is important that suggested biomarkers have predictive
value as indicated by sensitivity of 75% or greater as well as
specificity of 99.6% to be able to detect early stage cancer when it
is the most treatable [4].
One approach to identify disease biomarkers is to use
information-rich analytical tools such as omics-scale biological
methods to characterize the composition of the target tissue in
health and disease. In this case, it is important to understand the
biochemical alterations that are known to occur during neoplastic
transformation. The first energy metabolism alteration in cancer
cells was described by Otto Warburg, who showed cancer cells
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ATP production over the more efficient process of oxidative
phosphorylation by the mitochondria [13]. This requires the
cancer cells to increase their glucose uptake through the expression
of several isoforms of glucose transporters (GLUT 1 to 9) [14] and
to increase their glucose catabolism to compensate for the energy
production loss, a fact that can be exploited in the clinical
detection of neoplasm by positive emission tomography (PET)
imaging [15].
The molecular mechanisms involved in the hyperactive
glycolysis have been analyzed and some of key factors identi-
fied—including Akt, nuclear factor-kB (NF-kB), hypoxia-inducible
factor-1 (HIF1), and p53 [14,16,17,18,19,20]. The products of
these genes are involved in cellular activation, nutrient import, and
protection from apoptosis. These genes are known to interact in
complex hierarchical webs. For example, HIF-1 can be modulated
by other oncogenes such as Akt [14], K-Ras [21], and Her-2 [22]
to increase the expression of several glycolytic enzymes. Other
molecular mechanisms include transcriptional regulation by Myc
to increase expression of transporters and glycolytic enzymes—in
particular GLUT, hexokinase 2, and lactate dehydrogenase
[14,23]—as well as by the phosphoinositol-3-kinase (PI3K)/Akt/
mammalian target of rapamycin (mTOR) pathway [24,25], which
is commonly overactive in carcinomas [26]. In addition, tumor
metabolism differentially expresses glycoltyic isoenzymes, such as
pyruvate kinase (PKM2), which can shift between a dimer and a
tetramer to adapt to the energy requirements of the cells [27,28].
However, PKM2 can also be by-passed by the accumulation of
phosphoenolpyruvate (PEP) resulting in PEP-dependent phos-
phorylation and activation of phosphoglycerate mutase which
produces pyruvate directly from 3-phosphoglycerate [29]. Vander
Heiden et al. [29] hypothesized that this uncouples pyruvate
production from ATP generation, maintaining an ATP/AMP
ratio that does not inhibit glycolysis, and provides a significant
pool of pyruvate as an anabolic precursor. Most of the research on
tumor cell metabolism has focused on glucose utilization. When
glucose is limited, solid tumors are forced to catabolize alternative
substrates such as fatty acids, and amino acids as an alternative
energy source.
However, oncogenesis can result in a diverse panel of metabolic
alterations that could be tissue specific or generic across human
cancers. Therefore, a comprehensive metabolic analysis of solid
tumors could reveal valuable metabolites for both early diagnosis
of cancer as well as to monitor disease progression and/or
recurrence to inform clinical management of cancer patients.
These biomarkers could conceivably be used as surrogate
endpoints in clinical trials and could suggest new metabolic
targets for cancer management as well as provide complementary
targets for chemotherapy treatment. Metabolomics is a systematic
analytical tool used for identification of biochemical metabolites
from cellular processes, a term that includes several types of
analyses ranging for nuclear magnetic resonance spectroscopy
(NMR), mass spectrometry (MS), tracer-based studies, and
metabolic footprinting [30]. While each of these methods has
unique advantages, MS has established itself as the high-
throughput and industrially stable approach to assess both the
composition of diverse sample types as well as changes to that
composition following perturbation. Although metabolomics has
been around for decades, more recently it has garnered attention
as a translational tool for the identification and treatment of cancer
in the clinical setting, as well as for drug target development [31].
In a previous study, Denkert et al. [32] used gas chromatography
MS/time-of flight (GC-MS/TOF) to compare borderline ovarian
tumors to ovarian carcinomas. They identified 114 of 291 (39.1%)
compounds and found an increased in proteinogenic amino acids,
purines, pyrimides, and lipid membrane precursors in ovarian
carcinomas vs. borderline tumors and interpreted these data to
mean that carcinomas have higher cell proliferation rates. In
addition to tumor metabolic analysis, urine samples from ovarian
cancer patients have also been studied. Woo et al. [33] conducted a
metabolomic-based study to find urinary biomarkers for ovarian
and breast cancer using GC/MS. Two known biomarkers for
breast cancer and 3 new biomarkers for ovarian cancer were
identified: 1-methyladenosine, 3-methyluridine, and 4-androstene-
3,17-dione. The ovarian cancer biomarkers were related to
oxidative DNA damage and DNA methylation. Similarly, Slupsky
et al. [34] collected urine samples from patients with early- and
late-stage breast or ovarian cancer, as well as from healthy women,
to obtain a metabolic profile using NMR. The concentration of
specific metabolites decreased in patients with cancer, resulting in
a unique profile. Alterations in intermediates of the tricarboxylic
acid cycle (TCA) as well as molecules relating to energy
metabolism and amino acids were observed.
Prior to this study, however, the metabolome of the normal
ovary has not been studied, nor the changes that occur with
neoplastic transformation and metastatic disease progression. In
the present study, for the first time we report the metabolic profile
of the normal human ovary and compare it to the metabolic
profile of primary epithelial ovarian cancer (EOC) and metastatic
tumors resulting from initial EOC (MOC) using GC/MS and LC/
MS/MS.
Results
Identification of metabolites, statistical analysis, and
pathway analysis
In samples from our three groups (normal, EOC, and MOC),
364 molecules were identified (Table S1) when compared to the
Metabolon library containing 1,700 molecules. Identification was
based on retention time, charge (m/z), preferred adducts, and
fragmentation pattern of the molecule. The comprehensive library
allowed for rapid identification with a high fidelity. These
compounds included a large variety of classes, ranging from
simple amino acids and peptides to carbohydrates, lipids,
nucleotides, cofactors and vitamins, and xenobiotics (Fig. 1).
Data is a summation of individuals belonging to a group. Using
one-way ANOVA with a Tukey post-test to identify differentially
abundant metabolites across the three classes of tissue analyzed, 95
biochemicals were statistically significant and furthermore had a
p#0.05 in at least one of the pairwise comparisons (EOC vs.
Figure 1. Class distribution of identified metabolites. n=num-
ber of metabolites in each class.
doi:10.1371/journal.pone.0019963.g001
Metabolites in Ovary and Ovarian Cancer
PLoS ONE | www.plosone.org 2 May 2011 | Volume 6 | Issue 5 | e19963normal; MOC vs. normal; MOC vs. EOC). The identities of these
metabolites are given in Table S2. Using the abundance profiles of
these metabolites, supervised principal components analysis (PCA)
was performed, yielding good separation of the three groups (Fig. S1).
Using Ingenuity Pathway Analysis (IPA), we identified the top
15 canonical pathways involved in EOC (Table S3) and MOC
(Table S4). In almost all cases, these were related to amino acid
metabolism and biosynthesis. Also of note, pyrimidine metabolism,
purine metabolism, and glycoxylate and decarboxylate metabo-
lism pathways only appeared in the case of MOC.
Metabolic profile of the normal ovary and loss of
function upon transformation
The first principal component separated the non-transformed
ovarian samples from the transformed tissues (both EOC and
MOC), while the second principal component identified a further
set of biochemical alterations that corresponded with metastasis
(Figure S1). Evaluation of the loadings plot further classified the
compounds into loss/gain-of-function with either transformation
or metastasis. Four metabolites were in high abundance in the
ovary prior to neoplastic transformation: 1-methylimidazole
acetate (22.06 fold, p,0.001 in EOC; 22.18 fold, p,0.001 in
MOC), taurine (21.75 fold, p,0.001 in EOC, 21.97 fold,
p,0.001 in MOC), phenol sulfate (22.22 fold, p=0.0535 in EOC;
23.0 fold, p=0.0217 in MOC), and 6-phosphogluconate (21.64
fold, p=0.0538 in EOC, 21.92 fold, p=0.0264; Fig. 2). These
biochemicals have a significant drop in abundance upon
transformation. Two of these metabolites (methylimidazoleacetate
and 6-phosphogluconate) have previously been associated with
normal ovarian function and the drop in their abundance can be
considered a loss-of-function associated with transformation.
Methylimidazoleacetate is the main metabolite of histamine.
This end product of histamine catabolism is formed by N-
methylation in the imidazole ring to methylhistamine by histamine
methyltransferase and a subsequent oxidative deamination in the
side chain by type B monoamine oxidase. From studies it is known
that as much as 70–80% of the histamine metabolized in the body
is excreted in the urine as methylimidazoleacetate [35]. Thus,
urinary methylimidazoleacetate being the major and specific
histamine metabolite is a clear marker of any changes in histamine
metabolism in the body. Ovarian histamine production occurs by
tissue resident mast cells and has been shown to coordinate with
ovulation [36].
Taurine is not involved in protein synthesis and/or has limited
participation in biochemical pathways outside of peroxisomal
formation of N-acyl lipid conjugates, such as bile acids and fatty
acids. However, several functions have been demonstrated for
taurine—such as osmoregulation, membrane stabilization, detox-
ification, antioxidation, modulation of ion flux, and as an
inhibitory neurotransmitter or neuromodulator [37,38,39,40,41].
The roles of taurine in the reproductive system are multiple and
complex. Taurine is the predominant amino acid in genital
secretions—including seminal, uterine, and oviduct fluids [42,43].
It has been demonstrated that the ovary contains the mRNA of a
Figure 2. Significant metabolites present in the normal ovary and are reduced upon neoplastic transformation. 1-
methylimidazoleacetate and taurine analyzed by LC/MS positive ion spray; phenol sulfate and 6-phosphogluconate analyzed by LC/MS negative
ion spray. Box legend: + inside box represents mean value, bar inside box represents median value, upper bar represents maximum of distribution,
lower bar represents minimum of distribution, circle represents extreme data points.
doi:10.1371/journal.pone.0019963.g002
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10 mmol taurine/g tissue [45]. Taurine is also present in high
concentrations in the rat and human uterus, and its concentration
decreases with pregnancy [46,47]. Despite all these data, the roles
of taurine in the female reproductive system are largely unknown
and there are no previous studies about its localization in these
organs.
Phenol sulfate is a hepatically processed gut microfloral
metabolite, and 6-phosphogluconate is an intermediate in the
utilization of glucose within the pentose phosphate pathway,
potentially signifying that glucose is restricted from entry into the
pentose phosphate pathway in the healthy ovary and that upon
transformation there is a higher affinity mechanism in place for
this mechanism. This interpretation makes sense given that the
pentose phosphate pathway produces both ribose for nucleotide
biosynthesis, as well as two molar equivalents of NAD(P)H that
could mitigate oxidative stress and aid in glutathione recycling.
Six compounds differentiated transformed ovarian tissue
independent of whether the cancer was localized or metastatic
(PC1.0; PC2=0). These compounds included several quaternary
amines (betaine, carnitine, and erogthionine), the TCA cycle
intermediates malate and fumarate and N-acetylglycine. Increased
tissue quaternary amine concentrations are typically due to tissue
demand for either choline or carnitine as the transporters for
quaternary amines are selective but not specific [48]. In all,
thirteen compounds containing quaternary amines were found to
have increased tissue abundance in one or both of the ovarian
cancer groups compared to the non-transformed ovarian tissue
and two choline-containing lysolipids had significantly reduced
abundance in the transformed ovarian tissue.
Cancer cells have altered carbohydrate metabolism
One of the signature hallmarks of cancer is an altered glucose
metabolism. In 1929, Otto Warburg first proposed that cancer
cells utilized glucose differently than normal cells, preferring
glucose for anaeroblic glycolysis instead of oxidative phosphory-
lation for the generation of ATP [13], resulting in increased lactate
production and a lower pH than normal tissue, which in turn
impairs DNA repair mechanisms [49]. Our results showed an
increase in lactate in both EOC and MOC with a fold change of
1.46 (p,0.001) and 1.37 (p=0.0076), respectively, when compared
to normal ovarian tissue. Only MOC showed an increase in
glucose-6-phosphate (2.91 fold, p=0.0029). There were no
significant changes in glucose, pyruvate, acetylphosphate, phos-
phate, pyrophosphate, or citrate between groups (Fig. 3). The
increase in lactate coupled with no significant changes in citrate
levels, indicate that glycolysis was not impeded but rather
oxidative phosphorylation. Interestingly, another aspect of War-
burg metabolism, hexose phosphate abundance, was only elevated
in the MOC samples (data not shown).
The other carbohydrate with a significant increase in abun-
dance in transformed ovarian tissue was fucose (2.75 fold, p,0.001
in EOC; 1.81 fold, p=0.0103 in MOC). This finding may be due
to a loss of function of specific ovarian glycosylation pathways
since it has been demonstrated that normal ovarian tissue
expresses a specific protein fucosylation pathway that results in
the fucose moiety being directly coupled to the protein through
Ser/Thr [50]. This ovary-specific glycosylation pathway is also
unique in that the fucose is not the terminal sugar, but an internal
sugar in the O-linked oligosaccharide.
Increased fatty acid oxidation in EOC and MOC
As an alternative to oxidative phosphorylation for ATP
production, EOC and MOC prefer to utilize fatty acids as
indicated by an increase in several fatty acids (Fig. 4) involved in
fatty acid and carnitine metabolism—particularly carnitine (1.79
fold in EOC, p,0.001; 1.88 fold in MOC, p,0.001), acetylcarni-
tine (1.75 fold in EOC, p,0.001; 2.39 fold in MOC, p,0.001),
butyrylcarnitine (3.62 fold, p=0.0094 in EOC; 7.88 fold, p,0.001
in MOC), and propionylcarnitine increased 5.7 fold (p=0.0047) in
MOC only (Fig. 5). Carnitine has been recognized as a transport
protein that delivers fatty acids into the mitochondria for b-
oxidation. Endogenous acetylcarnitine has been used as an
indicator of mitochondrial health through the balance of acetyl-
CoA:CoA by transferring the acetyl group to carnitine to form
acetylcarnitine and thus provide acetyl groups for the synthesis of
sterols, fatty acids, and ketone bodies [51].
The ketone body 3-hydroxybutyrate (BHBA) was upregulated
8.63 fold (p=0.0056) in MOC compared to normal (Fig. 5). In
addition, the cytosolic pool of acetyl-CoA is essential of de novo
lipogenesis [52]. The excess production of cytoplasmic acetyl-coA
compared to the mitochondrial capacity for its incorporation into
the TCA cycle is demonstrated by the increased abundance of a
panel of N-acetyl amino acids in the cancerous tissues—including
N-acetylglutamate, N-acetylglycine, N-acetylthreonine, the neuro-
active amino acids N-acetylaspartate (NAA) and N-acetyl-
aspartylglutamate (NAAG), the polyamine degradation product
N-acetylputrescine, and even N-acetylglucosamine-6-phosphate.
Interestingly, we also found that the recently described
oncometabolite, 2-hydroxyglutarate had increased abundance in
EOC (3.06 fold, p=0.0114 in EOC; Fig. 5) [53].
Enhanced phenylalanine catabolism
Phenylalanine catabolism also results in the production of
ketones, namely phenylpyruvate and 4-hydroxypyruvate. Major
metabolites of phenylalanine catabolism were significantly in-
creased in EOC compared to normal (Fig. 6). Phenylpyruvate
increased 4.21 fold (p=0.0098) in EOC only compared to normal
but decreased 23.68 fold (p=0.036) in MOC compared to EOC.
Phenyllactate (PLA) increased 195.45 fold (p,0.0023) in EOC, a
finding which is typically attributed to insufficient activity of
phenylalanine hydroxylase [54]. Phenylacetate increased 1.93 fold
(p=0.0203) in EOC compared to normal only, whereas 4-
hydroxyphenylpyruvate was increased 17.82 fold (p=0.0069) in
EOC compared to normal. Phenylalanine, tyrosine, phenylace-
tylglutamine, and 4-hydroxyphenylacetate were not significantly
changed. Phenylalanine and its major metabolites—phenylpyru-
vate, PLA, and phenylacetate—induce oxidative stress in the
hippocampus and cerebral cortrex via generation of reactive
oxygen species, which was mitigated by a-tocopherol [55].
Phenylacetate has also been shown to have an inhibitory growth
effect in ovarian cancer cell lines [56], whereas PLA can promote
growth [57]. Therefore, it seems reasonable that ovarian cancer
would favor the production of PLA over other alternative
metabolites, consistent with our results. These metabolites are
generated by transamination of phenylalanine and subsequent
oxidation of the phenylpyruvate.
Increased levels of tocopherols in MOC
There are four main isoforms of tocopherols: a, b, d, and c, with
a-tocopherol being the most biologically active form, accounting
for approximately 90% of the Vitamin E found in animal tissues,
where it serves as an antioxidant to quench free radicals and
terminate lipid peroxidation [58,59]. Hence it serves as an
effective defense against radiation, which generates free radicals
from water or biomolecules [60]. Metabolomic analysis showed a
significant increase in a-, d-, and c-tocopherol levels in MOC. a-
tocopherol increased 1,160.41 fold (p,0.001) compared to normal
Metabolites in Ovary and Ovarian Cancer
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increased 1,775.51 fold (p,0.001) compared to normal and
1,950.08 fold (p,0.001) compared to EOC. c-tocopherol
increased 95.74 fold (p,0.001) compared to normal and 83.79
fold (p,0.001) compared to EOC (Fig. 7). As tocopherols are fat
soluble, they are carried in the blood packaged in lipoproteins,
mainly LDL and HDL, whereupon they are be transported to
tissue and undergo uptake by the same mechanism by which lipids
are delivered [58]. Uptake in the normal ovary is regulated by
lipoprotein receptors [59]. Tocopherols have also been implicated
in suppression of the immune system responsiveness by decreasing
the reactive oxygen species and/or altering arachidonic acid
metabolites [61]. Therefore, it seems reasonable that metastatic
cancer would accumulate them to suppress the immune response
and provide a defense against radiation treatment for cancer.
Enhanced oxidative stress response
Ophthalmate is an analog of the reduced form of glutathione
(GSH) with the thiol group of GSH replaced with a methyl group.
Ophthalmate can be synthesized from 2-aminobutyrate and
glutamate by the enzyme c-glutamyl cysteine synthetase (GCS)
to form c-glutamyl-2-aminobutyrate [62], which can be catalyzed
by glutathione synthetase (GS) to form ophthalmate [63] (Fig. 7).
Ophthalmate has been indicated as a biomarker of oxidative stress
as insufficient levels of GSH results in ophthalmate synthesis
through activation of GCS. GSH is one of the most abundant
intracellular antioxidants that protects the mitochondria from
endogenous oxygen radicals [64] and also keeps enzymes and
other cellular compounds in a reduced state [65], making it one of
the most important cellular antioxidants, as its depletion leads to
cell death. GSH has also been implicated in chemotherapy
resistance through the activation of multi-drug resistant transport-
er 1 (MDR-1) [66,67].
The oxidized form of glutathione (GSSG), GSH, c-glutamyl-2-
aminobutyrate, and ophthalmate can be detected in the serum in
mice [67] so all have the potential for biomarkers. However, to
date 2-aminobutyrate and ophthalmate have not been investigated
in ovarian cancer. Here we report of the first time, significant
increases of 2-aminobutyrate in both EOC (1.46 fold, p=0.0316)
and MOC (2.25 fold, p,0.001), suggesting an enhanced oxidative
Figure 3. The glycolytic pathway converting glucose to pyruvate for anaerobic fermation to produce lactate or aerobic respiration
of the citric acid for oxidative phosphorylation. Glucose, glucose-6-phosphate, fructose-6-phosphate, 3-phosphoglycerate, phosphoenolpyr-
uvate (PEP), pyruvate, lactate, and citrate analyzed by GC/MS. Box legend: + inside box represents mean value, bar inside box represents median
value, upper bar represents maximum of distribution, lower bar represents minimum of distribution, circle represents extreme data points.
doi:10.1371/journal.pone.0019963.g003
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Fig. 8). However, there were no significant changes in glutathione
(reduced and oxidized states) or glutamate.
Increased production of NAA and NAAG
N-acetylasparate (NAA) is a free amino acid found in the brain
at very high concentrations that functions as an osmolyte in fluid
balance to protect neurons against osmotic stress [68,69]. It is also
thought to serve as a source of acetate for lipid and myelin
synthesis [70] and contribute glutamate for energy production in
the neuronal mitochondria through a series of reactions [71,72].
NAA is synthesized from L-asparate and acetyl-CoA by the
enzyme L-asparate-N-acetyl transferase and hydrolyzed by the
enzyme aspartoacylase II. NAA serves as a precursor for N-
ascetyl-aspartyl-glutamate (NAAG) using the enzyme NAA
synthetase (Fig. 8). Due to its packaging with glutamate, the
physiological role for NAAG has been difficult to identify,
however, it fulfills the criteria of a neurotransmitter as it is
packaged into synaptic vesicles and released in a Ca
2+-dependent
manner from nerve terminals [73]. It has been proposed to serve
as a shuttle for glutamate to activate the glutamate receptor
mGluR3 due to the cytotoxic nature of glutamate [74,75]. More
recently, it has been used to diagnose brain disorders. Moreover,
NAA concentrations have been found in a patient with ovarian
mucinous cystadenoma [76] and in ovarian cyst fluid of serous
ovarian tumors [77], although a physiological role in the ovary has
not been determined. Here we report that NAA and NAAG, two
free amino acids, were detected in the normal ovary with
significantly increased levels in EOC showing a fold change of
3.50 (p=0.0301) and 2.19 (p=0.0352), respectively, with further
increases in MOC with a fold change of 85.60 fold (p,0.001) and
8.09 (p,0.001), respectively (Fig. 9).
NAAG is broken down by N-acetylated alpha-linked acidic
dipeptidase (NAALADase), a NAAG-specific catabolic enzyme
[78]. NAALADase is composed of three family members:
NAALADase I, NAALADase L, and NAALADase II. NAALA-
Dase II has been found to be highly expressed in the ovary when
identified by Northern blot and reverse-transcription PCR [79].
Figure 4. Upregulated fatty acids in EOC and/or MOC compared to normal ovarian tissue.
doi:10.1371/journal.pone.0019963.g004
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Metabolomics has been widely used to identify biomarkers for
various disease states—including diabetes [80] and atherosclerosis
[81]—using blood, urine, cells, and tissue. Of import, metabo-
lomics has provided a comprehensive technique to identify
biomarkers for cancer—including breast [82,83,84,85], ovarian
[32,33,86], prostate [87,88], colorectal [89,90,91], and gastric
cancer [92]. Identification of biomarkers is of the utmost
importance as it can help diagnose diseases at an earlier stage,
leading to a better prognostic outcome, when used in conjunction
with existing methods, such as transvaginal ultrasound in the case
of ovarian cancer.
In this study, the comprehensive metabolic profile of normal
ovaries, EOC, and MOC were compared using GC/MS or LC/
MS/MS. Significant changes in energy utilization were detected as
well as an enhanced oxidative stress response. Similar to the study by
Denkert et al. [32], we have found increased levels of amino acids in
EOC and MOC vs. normal. However, contrary to their study, the
lysolipidlevelswere either notsignificantlychangedor downregulated
in EOC and/or MOC. Woo et al. [33] found urinary biomarkers for
ovarian cancer using GC/MS related to DNA oxidative damage and
DNA methylation: 1-methyladenosine, 3-methyluridine, and 4-
androstene-3,17-dione. We found no significant changes in N1-
methyladenosine or 4-androstene-beta,17beta diol disulfate based on
tissuesamples,perhapsduetothehighamountofGSSGfoundinour
Figure 5. Carnitine and fatty acid metabolites. Carnitine, acetylcarnitine, butrylcarnitine, and propionylcarnitine analyzed by LC/MS positive ion
spray. 2-hydroxyglutarate and 3-hydroxybutyrate analyzed by GC/MS. Box legend: + inside box represents mean value, bar inside box represents
median value, upper bar represents maximum of distribution, lower bar represents minimum of distribution, circle represents extreme data points.
doi:10.1371/journal.pone.0019963.g005
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from oxidative damage or from a more efficient excretion of the
metabolites in these patients. We also found increased tocopherols in
MOC, which are best known for their antioxidant properties. More
recently, urine metabolite profiling in breast and ovarian cancer
showed that metabolite concentrations correlated with both cancers
compared to healthy individuals [34]. Consistent with the aforemen-
tioned study, Odunsi et al. [86] were able to separate sera from
healthy individuals from that of EOC patients using (1)H-NMR
spectroscopy. Applying unsupervised PCA analysis as well as
Figure 6. Phenylalanine metabolic pathway. Phenylalanine and tyrosine analyzed by LC/MS pos.; phenylpyruvate, phenyllacetate,
phenylacetylglutamine, phenylactate, and 4-hydroxyphenylpyruvate via LC/MS negative ion spray; 4-hydroxyphenylacetate via GC/MS. Box legend:
+ inside box represents mean value, bar inside box represents median value, upper bar represents maximum of distribution, lower bar represents
minimum of distribution, circle represents extreme data points.
doi:10.1371/journal.pone.0019963.g006
Figure 7. Three of the main tocopherol levels in normal, EOC, and MOC. Tocopherols analyzed via GC/MS. Box legend: + inside box
represents mean value, bar inside box represents median value, upper bar represents maximum of distribution, lower bar represents minimum of
distribution, circle represents extreme data points.
doi:10.1371/journal.pone.0019963.g007
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ophthalmate analyzed by LC/MS positive ion spray. Box legend: + inside box represents mean value, bar inside box represents median value, upper
bar represents maximum of distribution, lower bar represents minimum of distribution, circle represents extreme data points.
doi:10.1371/journal.pone.0019963.g008
Figure 9. NAA and NAAG biosynthesis pathway. NAA and NAAG analyzed via LC/MS negative and LC/MS positive ion spray, respectively. Box
legend: + inside box represents mean value, bar inside box represents median value, upper bar represents maximum of distribution, lower bar
represents minimum of distribution, circle represents extreme data points.
doi:10.1371/journal.pone.0019963.g009
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allowed for pattern recognition. They were able to correctly identify
increases in alanine, valine, glucose, and 3-hydroxybutyrate (a ketone
body) in EOC sera. In our samples, we showed an increase of 3-
hydroxybutyrate in MOC with a borderline significant increase in
EOC. However, the other metabolites were not significantly altered.
Additional metabolic analysis in colorectal tissue [89,91] and in
gastriccancermetastases[92]samplesshowedincreasesinglycolysis
shown by the increase in lactate and fatty acid metabolism, and
decreases in TCA intermediates. Lactate and phenylalanine have
yielded satisfactory sensitivity and accuracy in differentiating oral
squamous cell carcinomafromoral leukoplakia [93]; however, these
metabolites could be generic across multiple cancers.
One of the proposed biomarkers for tumor progression and
invasiveness in prostate cancer is sarcosine, also known as N-
methylglycine [94], although there is some debate whether
sarcosine can be detected in the serum [95] or urine [96]. Sarcosine
can be synthesized from glycine by the enzyme glycine N-
methylransferase or from dimethylglycine by the enzyme dimethyl-
glycine dehydrogenase, which in turn is demethylated from betaine.
In our samples, we found a significant increase in betaine in both
EOC and MOC compared to normal. However, dimethylglycine
and sarcosine were not significantly different, possibly due to a high
biological variability between samples, which could be clarified with
an increased sample size.
Based on the data we have collected, we have identified possible
candidates for biomarker analysis for both preliminary cancer
diagnosis and metastatic disease progression. The dramatic
increase of tocopherols in MOC makes these molecules attractive
candidates for aggressiveness and/or progression. Further inves-
tigation is needed to determine the potential utility of these initial
findings.
Materials and Methods
Histopathology
For metabolic profiling, 30 patient tissues were obtained from
University of Alabama, Birmingham, Comprehensive Cancer
Center and stored at 280uC. Type and stage was determined by
evaluation by a pathologist. Tissues included 12 normal ovarian
samples (mean age 48.667.6 years), 11 primary ovarian
adenocarcinomas ranging from Stage I through Stage IIIC (mean
age 56.569.8 years), and 7 metastatic tumors in the omentum
resulting from initial ovarian adenocarcinomas ranging from Stage
IIIC through Stage IV (mean age 6268.2 years). Patients with
previous diseases and treatments were excluded from the study.
Metabolic Profiling
100 mg of frozen biopsy tissue was submitted to Metabolon, Inc.
(Durham, NC) for sample extraction and analysis. In brief,
Metabolon performed cold methanol extraction of mechanically
disaggregated tissue samples and these extracts were split into
three aliquots. The reproducibility of the extraction protocol was
assessed by the recovery of xenobiotic compounds spiked into
every tissue sample prior to extraction. These aliquots were
processed and characterized by one of the three analytical
methods previously described: UHPLC-ESI-MS/MS in the
positive ion mode, UHPLC-ESI-MS/MS in the negative ion
mode and sialylation followed by GC-EI-MS. Chromatographic
timelines were standardized using a series of xenobiotics that elute
at specified intervals throughout each chromatographic run. The
technical variability of each analytical platform was assessed by
repeated characterization of a pooled standard that contained an
aliquot of each sample within the study. The platform for sample
analysis has been described in detail [97,98]. However, the
combination of the Metabolon platform with ovarian tissue is
novel.
Supporting Information
Figure S1 Supervised PCA separated normal ovarian tissue
from ovarian cancer (PC1; blueRgreen and purple) and localized
tumor from metastasis (PC2; greenRpurple).
(TIF)
Table S1 List of metabolites identified through mass spectrom-
etry.
(XLS)
Table S2 ANOVA analysis of metabolites grouped by class of
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